How can Humanized Mouse Models be Used to Study Cancer & the Development of New Immune-Targeted Therapies?

Life Sciences, Drug Discovery & Development, Preclinical,
  • Tuesday, November 08, 2022

In this webinar, the featured speakers will describe humanized immune system mouse models and how they can support preclinical drug development. The webinar will explore how humanized mouse models allow the assessment of immune-checkpoint inhibitors, cell therapies, vaccines or antibodies and other drugs.

First, speaker Sebastien Tabruyn will talk about the advantages of the humanized mouse models with human immune system (HIS) for immunology and oncology research and preclinical study techniques.

Next, speaker Wout de Wispelaere will present an application of humanized mice in the study of aggressive tumors: uterine leiomyosarcomas (uLMS) and a pathway to initiate an anti-tumor adaptive immune response.

Register to learn how humanized mouse models can be used to study cancer and the development of new immune-targeted therapies.


Wout de Wispelaere, PhD Researcher, University of KU Leuven

Wout obtained his master’s degree in bioscience engineering from University of KU Leuven and is currently pursuing his PhD in the laboratory of Gynecological Oncology (KUL) and the Laboratory of Translational Genetics (KUL-VIB). His research is focused on identifying combination treatment strategies to enhance immune checkpoint blockade response in uterine leiomyosarcomas, a ‘cold’ and very aggressive smooth muscle tumor of the uterus with dismal prognosis.

Message Presenter

Sebastien Tabruyn, PhD, Chief Scientific Officer, General Manager, TransCure bioServices

Chief Scientific Officer and General Manager. Sebastien Tabruyn holds a PhD in molecular biology from the University of Liege (Belgium). After 20 years of experience as Project leader in renowned international academic research institutes including UCSF (California, USA), the Centre for Cancer Biology (Adelaide, Australia) and the University of Maastricht (Netherlands), he joined TransCure bioServices in 2013 to develop the first IO humanized mouse models. Sebastien Tabruyn published more than 30 peer-reviewed publications mostly focused on oncology, inflammation, immunity and angiogenesis.

Message Presenter

Who Should Attend?

Preclinical researchers working in the immuno-oncology area, from pharmaceutical and biotech companies.

What You Will Learn

Attendees will learn:

  • The main characteristics of a full human immune system mouse model
  • How humanized mice allow the assessment of immune-checkpoint inhibitors, cell therapies, vaccines or antibodies
  • How to select the best tumor model for immunology and oncology research
  • A case study on an innovative solution to treat an aggressive tumor: uterine leiomyosarcomas (uLMS)

Xtalks Partner

TransCure bioServices

TransCure bioServices offers pre-clinical contract research services to pharmaceutical, biotech, start-up and academic researchers who need faster, smarter and cost-effective solutions for drug profiling. Uniquely designed animal models with functional humanized systems have been developed to provide predictive in vivo pharmacology testing in the field of oncology, immuno-oncology, inflammation, autoimmune diseases, anti-infective and vaccine development.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account